Health technology assessment (HTA) is a multidisciplinary process that summarizes information about the medical, social, economic and ethical issues related to the use of medical technologies in a systematic, transparent, unbiased, robust manner.
The key objective of HTA is to advise policymakers and providers about the necessity of adopting and appropriateness of reimbursing pharmaceuticals.
Most developed countries have functioning HTA framework on different levels (national, regional, hospital-based).
HTA plays an important role in the market access landscape for medical technologies. Very often, HTA is a formal part of the reimbursement process (e.g., in France or England), or it is not formally connected to the reimbursement process, but it significantly impacts the adoption of technologies.
Market access professionals should closely monitor new initiated and published HTAs for the products under their supervision. The key challenge for effective monitoring is a large number of HTA organizations, language barrier and lack of time to do such monitoring properly.
MTRC, a market leader in European market access, is bringing a new service to enable effective time- and cost-effective monitoring of HTA activity in Europe and globally: HTA Alerts.
This service is focused on pharmaceuticals, gene and cell therapies, and vaccines. If you are interested in HTA Alerts for medical procedures, devices and in-vitro diagnostic tests, visit a dedicated page for HTA Alerts - Med Tech